{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-169756","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.292865+00:00","generated_at":"2026-06-01T01:01:38.230303+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cogent reaches FDA alignment on MS2D2 endpoint for SUMMIT trial; enrollment timeline reaffirmed","bullets":["FDA alignment on novel patient-reported outcome measure MS2D2 for Part 2 of SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM).","SUMMIT Part 2 enrollment on track to complete Q2 2025; top-line results expected by end of 2025.","APEX study (Advanced SM) enrollment to complete end of 2024; top-line results mid-2025.","PEAK study (GIST) enrollment expected to complete Q3 2024; top-line results by end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-169756","json":"https://secwatch.observer/filing/0001193125-24-169756.json","markdown":"https://secwatch.observer/filing/0001193125-24-169756.md","text":"https://secwatch.observer/filing/0001193125-24-169756.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312524169756/0001193125-24-169756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312524169756/d792910d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:01:38.230303+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}